Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last --
Change Today 0.00 / 0.00%
Volume 0.0
AMBX On Other Exchanges
All times are local (Market data is delayed by at least 15 minutes).

ambrx inc (AMBX) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for AMBRX INC (AMBX)

Related News

No related news articles were found.

ambrx inc (AMBX) Related Businessweek News

No Related Businessweek News Found

ambrx inc (AMBX) Details

Ambrx, Inc. discovers and develops protein therapeutics. The company develops a pipeline of product candidates that include antibody drug conjugates (ADCs), bi- and multi-specific drug conjugates, and long-acting therapeutic proteins. Its ADCs comprise ARX788, a human epidermal growth factor 2 (HER2) antibody, which is in preclinical development for the treatment of breast cancer and other solid tumors that express and overexpress HER2. The company’s long-acting proteins include of ARX201, a human growth hormone, which has completed a Phase IIb clinical trial in young adults with growth hormone deficiency; and ARX328, which is in preclinical development as a leptin-replacement therapy in patients with lipodystrophy and weight management. Its ADC and bi-specific product candidates include PSMA ADC for the treatment of metastatic castration-resistant prostate cancer and glioblastoma multiforme; CD70 ADC for the treatment of renal and nasopharyngeal cancers; Bi-specific Anti-CD3 X Folate for the treatment of ovarian cancer; and CD184-FK506 ADC for the treatment of immunological diseases. The company has collaborations with Bristol-Myers Squibb Company, Merck Sharp & Dohme Corp., Eli Lilly and Company, Agensys, Inc., Zhejiang Medicine Co., Ltd., and Zhejiang Hisun Pharmaceutical Co., Ltd. Ambrx, Inc. was founded in 2003 and is based in La Jolla, California.

74 Employees
Last Reported Date: 06/9/14
Founded in 2003

ambrx inc (AMBX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: --
Co Founder and Senior Advisor
Total Annual Compensation: --
Principal Financial & Accounting Officer and ...
Total Annual Compensation: --
Chief Business Officer
Total Annual Compensation: --
Vice President of Intellectual Property
Total Annual Compensation: --
Compensation as of Fiscal Year 2014.

ambrx inc (AMBX) Key Developments

Ambrx, Inc. Presents at Boston Biotech Conferences LLC's The East Meets West CEO conference, Jan-10-2015 03:10 PM

Ambrx, Inc. Presents at Boston Biotech Conferences LLC's The East Meets West CEO conference, Jan-10-2015 03:10 PM. Venue: Four Seasons Hotel, 757 Market St, San Francisco, CA 94103, United States. Speakers: Lawson MacArtney, Chief Executive Officer, President and Director.

Ambrx Seeks Acquisitions

Ambrx, Inc. has filed an IPO in the amount of $86.25 million. Ambrx may use a portion of the net proceeds to in-license, acquire or invest in complementary businesses or products. However, Ambrx has no current commitments or obligations to do so.

Ambrx, Inc. and Zhejiang Hisun Pharmaceutical Co., Ltd. to Collaborate on the Development and Commercialization of Bispecifics for Cancer

Ambrx Inc. and Zhejiang Hisun Pharmaceutical Company Ltd. announced a collaboration for the development and commercialization of bispecifics based on Ambrx technology for the treatment of cancer. Hisun will have commercial rights to the products in China, while Ambrx will retain commercial rights outside of China and will be entitled to receive royalties on sales of the products in China. Hisun will manufacture the product to cGMP standards for clinical and commercial supplies on a global basis.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AMBX:US $0.00 USD 0.00

AMBX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AMBX.
View Industry Companies

Industry Analysis


Industry Average

Valuation AMBX Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AMBRX INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at